Acids in your body are a major detriment to your health. If you can’t diminish the level of body acids, you will not have decent health. Acids in your body produce pain and disease, which requires your immune system to fight this condition, which results in lowering your immune system.
There is one big reason that minerals are extremely important. If certain minerals are deficient in your body then those genes that fight cancer are not activated.
Selenium is one such mineral that is necessary to activate certain genes to help you suppress the formation of cancer cells. Here is what selenium does in your body to fight cancer and improve your immune system.
So, you can see that when you have a cold, or flu you are fighting a virus, or bacteria. To lessen the period, and strength of these conditions, your immune system has to be strong. You don’t want a cold or flu to turn into pneumonia, or any other respiratory condition.
It’s time to welcome back the short days, crisp air, and colorful leaves of Fall. Though the season is beautiful, it does require a bit more of an effort to keep yourself healthy and happy than summertime. When you factor in less daylight and the upcoming seasonal gatherings, it’s easy to feel like there isn’t enough time left in the day for ourselves. On Wednesday, September 27th, fitness, nutrition and lifestyle expert, Kelli Calabrese, will be available to discuss her pro tips on how to prepare yourself for the colder months, including easy ways to boost the immune system, calm the mind, relax the body and stay healthy.
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
The U.S. Food and Drug Administration (FDA) is alerting pregnant women about the risks of listeriosis, a foodborne disease that can severely affect a pregnant women and her unborn child.
Listeria can affect all races and ethnic groups, but pregnant women are 10 times more likely than other healthy adults to get listeriosis due to hormonal changes that affect the immune system during pregnancy. Pregnant Hispanic women are about 24 times more likely than the general population to get listeriosis. A pregnant mother may pass Listeria onto her unborn baby without even knowing it because she doesn’t feel sick at all, yet the disease can lead to miscarriage, stillbirth, premature labor, the delivery of a low birthweight infant, a wide range of health problems for a newborn, or even infant death.
To view the multimedia release go to:
https://www.multivu.com/players/English/7953451-fda-listeriosis-prevention-pregnant-women/
Today, WebMD released Path to a Breakthrough, a five-part original video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, Path to a Breakthrough sheds light on how medical innovations, including Precision Medicine, Immunotherapy, and Biologics, are providing doctors with powerful new tools to treat disease, alleviate symptoms, and in some cases, reverse the course of debilitating illness.
In this extraordinary new series, WebMD and Roberts share the stories of Cara, a 4-year-old girl who lost, then regained her ability to walk from the clues hidden in her genetic makeup; Trevor, a man diagnosed with stage IV Lymphoma in the prime of his life, and the doctor who helped him harness his own immune system for a nontoxic cancer treatment; Kevin, whose pain from dirt bike racing injuries was nothing compared to the excruciating pain of Rheumatoid Arthritis; Falisha, whose life-changing diagnosis of Multiple Sclerosis was alleviated by biologics; and Rebecca, whose debilitating Psoriasis led to blindness.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579754-webmd-path-to-a-breakthrough/
https://youtu.be/iOOqi_Xf978 Alarming newspaper and industry reports show that no one, including small businesses, is immune from a potential data security breach. The best way to protect yourself is with a comprehensive security protection plan and knowing some of the tricks hackers use that can cost you time, money and spur mistrust from your customers. Here are four risks that could make you a target for hackers – and how you can fix them.
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
In an effort to inform children and their families about the importance of food safety, U.S. Department of Agriculture (USDA) and the Ad Council are joining 20th Century Fox to launch a series of public service advertisements (PSAs) featuring footage from the upcoming film Alvin & the Chipmunks: The Road Chip.
An estimated 1 in 6 (48 million) Americans get sick from foodborne illness each year, resulting in roughly 128,000 hospitalizations and 3,000 deaths, according to the Centers for Disease Control and Prevention. Children are among the most vulnerable to food poisoning because their immune systems are still developing, so parents and caregivers need to take extra precautions when preparing food for children under five.
The new PSAs, featuring everyone’s favorite Chipmunks – Alvin, Simon, and Theodore – highlight the four food safety steps consumers can use to prevent foodborne illness. The Chipmunks’ antics and hilarious situations in which they find themselves provide a perfect platform to illustrate these four steps: Clean, Separate, Cook, and Chill. The PSAs help explain actions anyone can take to safely prepare their food, using the Chipmunks as the tool to bring fun and relevancy to a serious topic. The partnership includes TV, radio, out-of-home and web advertising, and parents and children can also find kid-friendly activities that further reinforce the food safety steps by visiting FoodSafety.gov.
To view the multimedia release go to:
http://www.multivu.com/players/English/7652251-ad-council-food-safety/
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
